Floatz logo

Durvalumab

Peritoneal Neoplasms

AstraZenecamonoclonal_antibodyPhase 1/2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Peritoneal Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Eli Lilly and Company
Phase 3BBB
Inno-206
Eli Lilly and Company
Phase 3BBB
FLUOROURACILUM
AstraZeneca
Phase 2BB
Eloxatin
Sun Yat-sen University
Phase 2/3BB
Patupilone
Novartis Pharmaceuticals
Phase 3BB

View all 44 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →